InVitae Corp (NASDAQ:NVTA) Director Geoffrey Crouse purchased 15,000 shares of the stock in a transaction that occurred on Friday, November 18th. The shares were purchased at an average cost of $6.25 per share, for a total transaction of $93,750.00. Following the completion of the acquisition, the director now directly owns 34,259 shares of the company’s stock, valued at approximately $214,118.75. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

InVitae Corp (NASDAQ:NVTA) traded up 12.54% during trading on Monday, reaching $6.82. 1,065,313 shares of the company’s stock were exchanged. The firm’s market capitalization is $221.27 million. InVitae Corp has a 52 week low of $5.66 and a 52 week high of $11.85. The stock has a 50-day moving average price of $7.67 and a 200 day moving average price of $8.27.

InVitae Corp (NASDAQ:NVTA) last announced its earnings results on Monday, November 7th. The company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by $0.05. The firm had revenue of $6.30 million for the quarter, compared to analyst estimates of $7.50 million. InVitae Corp’s revenue for the quarter was up 186.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.71) earnings per share. Equities research analysts forecast that InVitae Corp will post ($3.02) earnings per share for the current fiscal year.

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in InVitae Corp by 7.0% in the second quarter. Vanguard Group Inc. now owns 636,857 shares of the company’s stock worth $4,706,000 after buying an additional 41,420 shares during the period. BlackRock Investment Management LLC raised its position in InVitae Corp by 20.2% in the second quarter. BlackRock Investment Management LLC now owns 354,076 shares of the company’s stock worth $2,617,000 after buying an additional 59,453 shares during the period. BlackRock Fund Advisors raised its position in InVitae Corp by 210.4% in the second quarter. BlackRock Fund Advisors now owns 583,714 shares of the company’s stock worth $4,314,000 after buying an additional 395,679 shares during the period. BlackRock Institutional Trust Company N.A. raised its position in InVitae Corp by 59.0% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 315,984 shares of the company’s stock worth $2,335,000 after buying an additional 117,212 shares during the period. Finally, HighTower Advisors LLC purchased a new position in InVitae Corp during the second quarter worth $565,000.

A number of brokerages recently issued reports on NVTA. Zacks Investment Research downgraded shares of InVitae Corp from a “buy” rating to a “hold” rating in a report on Saturday. Leerink Swann began coverage on shares of InVitae Corp in a report on Thursday, November 10th. They set an “outperform” rating and a $12.00 price target on the stock. Benchmark Co. reissued a “neutral” rating on shares of InVitae Corp in a report on Tuesday, November 8th. TheStreet downgraded shares of InVitae Corp from a “hold” rating to a “sell” rating in a report on Thursday, September 15th. Finally, JPMorgan Chase & Co. upped their price objective on shares of InVitae Corp from $12.00 to $14.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $10.81.

About InVitae Corp

Invitae Corporation (Invitae) utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

5 Day Chart for NASDAQ:NVTA

Receive News & Stock Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related stocks with our FREE daily email newsletter.